VISCHER is advising Inthera Bioscience AG, a Zurich based biopharmaceutical company, developing first-in-class targeted small molecule therapies for solid tumors.  The CHF10.5m (€9.6m) series A financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo

The VISCHER team includes Christian Wyss (Partner), Dania Salvisberg-Schneider (Senior Associate), both Corporate and Nadia Tarolli (Partner), Tax.